This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety Study of FP-1039 To Treat Cancer

This study has been completed.
Information provided by (Responsible Party):
Five Prime Therapeutics, Inc. Identifier:
First received: May 27, 2008
Last updated: March 5, 2013
Last verified: March 2013
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.

Condition Intervention Phase
Advanced Cancer Drug: FP-1039 Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of FP-1039 in Subjects With Metastatic or Locally Advanced Unresectable Solid Tumors

Further study details as provided by Five Prime Therapeutics, Inc.:

Primary Outcome Measures:
  • Safety and tolerability [ Time Frame: 4 weeks ]

Enrollment: 39
Study Start Date: July 2008
Study Completion Date: June 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Single ascending doses
Drug: FP-1039
Intravenous weekly administration


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with metastatic or locally advanced unresectable solid tumors for which standard curative or supportive measures do not exist or are no longer effective
  • Male or female 18 years of age or older

Exclusion Criteria:

  • Presence or history of melanoma
  • Primary brain tumor
  • Presence or history of glaucoma
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00687505

United States, Michigan
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
United States, Texas
START (South Texas Accelerated Research Therapeutics)
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Five Prime Therapeutics, Inc.
  More Information

Responsible Party: Five Prime Therapeutics, Inc. Identifier: NCT00687505     History of Changes
Other Study ID Numbers: FP1039-001
Study First Received: May 27, 2008
Last Updated: March 5, 2013 processed this record on August 23, 2017